silver anniversary conference - american diabetes association · silver anniversary conference on...

professional.diabetes.org/sfl

Seminole Hard Rock Hotel & Casino - Hollywood, FL 1 Seminole Way, Hollywood, FL 33314

Friday & Saturday Friday & Saturday Friday & Saturday

September 9 & September 10, 2016 September 9 & September 10, 2016 September 9 & September 10, 2016

Silver Anniversary ConferenceSilver Anniversary ConferenceSilver Anniversary ConferenceSilver Anniversary Conference on Diabetes Mellitus:

Silver Anniversary Conference on Diabetes Mellitus: Reflec*ng Back, Moving Forward

Target AudienceTarget AudienceTarget AudienceTarget Audience

With its mul*disciplinary focus, the American Diabetes Associa*on’s 25th Annual Conference on Diabetes

Mellitus draws a1endees from across the health care spectrum and across the state of Florida. This is

South Florida’s premier diabetes mee*ng, where a1endees come to hear cu4ng-edge research translated

into clinical prac*ce, leading-edge treatment updates and the latest informa*on in diabetes management.

This mee*ng is designed specifically for physicians, pharmacists, physician assistants, nurse prac**oners,

nurses, die**ans, cer*fied diabetes educators and other health care professionals who care for pa*ents

with diabetes, at risk for diabetes, and who manage diabetes-related complica*ons.

Learning ObjectivesLearning ObjectivesLearning ObjectivesLearning Objectives

♦ Explain the cri*cal role of therapeu*c lifestyle interven*on for cardiometabolic health.

♦ Discuss the ADA/AACE glycemic targets in the hospital.

♦ Examine new classifica*on schema and therapeu*c implica*ons for diabetes

management.

♦ Outline the mechanism of ac*on of SGLT2 inhibitors.

♦ List the drug classes for treatment of type 2 diabetes.

♦ Iden*fy the mechanism of ac*on, advantages and disadvantages of available agents

used in the treatment of type 2 diabetes.

♦ Describe the history of pancreas transplanta*on.

Accreditation StatementsAccreditation StatementsAccreditation StatementsAccreditation Statements

Physicians

The American Diabetes Associa*on is accredited by the

Accredita*on Council for Con*nuing Medical Educa*on

(ACCME) to provide con*nuing medical educa*on for

physicians.

The American Diabetes Associa*on designates this edu-

ca*on ac*vity for a maximum of 11.75 AMA PRA Catego-

ry 1 credit(s)™. Physicians should only claim credit com-

mensurate with the extent of their par*cipa*on in the

ac*vity.

Doctors of Osteopathy

Category 2 credit will be awarded for formal educa*onal

programs that are ACCME-accredited or AAFP-approved.

Physician Assistants

AAPA accepts cer*ficates of par*cipa*on for educa*onal

ac*vi*es cer*fied for AMA PRA Category 1 Credit™ from

organiza*ons accredited by ACCME or a recognized state

medical society. Physician assistants may receive a maxi-

mum of 11.75 hours of Category I credit for comple*ng

this program.

Nurses

The American Diabetes Associa*on is accredited as a

provider of con*nuing nursing educa*on by the Ameri-

can Nurses Creden*aling Center’s COA.

California Board of Registered

Nursing

The American Diabetes Associa*on is also a provider ap-

proved by the California Board of Registered Nursing,

Provider No. CEP-12196. This ac*vity is approved for

11.75 contact hours.

Dietitians

The American Diabetes Associa*on is a

Con*nuing Professional Educa*on (CPE)

Accredited Provider with the Commission

on Diete*c Registra*on (CDR). Regis-

tered die**ans (RDs) and diete*c techni-

cians registered (DTRs) will receive 11.75

con*nuing professional educa*on units

(CPEUs) for comple*on of this program/material.

Pharmacists

The American Diabetes Associa*on is ac-

credited by the Accredita*on Council for

Pharmacy Educa*on as a provider of con*n-

uing pharmacy educa*on. The American

Diabetes Associa*on designates these ses-

sions as Knowledge-based per ACPE guidelines. To view

the UAN’s and learning objec*ves for each session,

please visit professional.diabetes.org/sfl aGer September

1st and click “Con*nuing Educa*on for Pharmacists.”

Attention Pharmacists: Upon closing of the

online evalua*on (September 30, 2016), the American

Diabetes Associa*on will upload the needed pharmacy-

related con*nuing educa*on informa*on to the CPE

Monitor within 60 days. The ADA is not responsible for

uploading credits aGer the evalua*on closes on Septem-

ber 30, 2016. For ques*ons, please contact profession-

aleduca*[email protected].

Certified Diabetes Educators

To sa*sfy the requirement for renewal of cer*fica*on by

con*nuing educa*on for the Na*onal Cer*fica*on Board

for Diabetes Educators (NCBDE), con*nuing educa*on

ac*vi*es must be diabetes related and approved by a

provider on the NCBDE List of Approved Providers

(www.ncbde.org). NCBDE does not approve con*nuing

educa*on. The American Diabetes Associa*on is on the

NCBDE List of Approved Providers.

CONTENT VALIDATION STATEMENTS

All recommenda*ons involving clinical medicine are

based on evidence accepted within the profession of

medicine as adequate jus*fica*on for their indica*ons

and contraindica*ons in the care of pa*ents; AND/OR

All scien*fic research referred to or reported in support

or jus*fica*on of a pa*ent care recommenda*on con-

forms to generally accepted standards of experimental

design, data collec*on, and analysis.

Successful Completion Statement Cer*ficates of Comple*on/A1endance are provided to registered a1endees based upon comple*on of the online evalua*on that will be available at

h1p://professional.diabetes.org/sfl through September 30, 2016. For ques*ons regarding con*nuing educa*on, please contact

professionaleduca*[email protected].


P l a n n i n g C o m m i t t e e

Paul Aoun, DO, PhD Clinical Endocrinologist, Palm Beach Diabetes &

Endocrine Specialists; University of Miami

Miller School of Medicine; JFK Medical Center

Boynton Beach, FL

Pamela C. Arnold, MSN, APRN, BC-

ADM, CDE Diabetes Program Manager

Medical University of South Carolina

Charleston, SC

Katherine Chadwell, DNP, MBMSc,

ARNP, GNP-BC, CPHQ Associate Professor

Florida Atlan*c University

Chris*ne E. Lynn College of Nursing

Boca Raton, FL

James R. Gavin III, MD, PhD CEO and Chief Medical Officer, Healing Our

Village, Inc.; Clinical Professor of Medicine,

Emory University School of Medicine

Atlanta, GA

Harvi Anne Lipshultz, BS Pharm,

PharmD Clinical Research Pharmacist

Broward Health

Fort Lauderdale, FL

Mudit Jain, MD, FACE, ECNU, CDE Director, Diabetes & Thyroid Care Center of

Excellence; Clinical Assistant Professor,

Nova Southeastern University; Florida Interna-

*onal University

Planta*on, FL

Michael Ozner, MD, FACC, FAHA Medical Director, Center for Preven*on and

Wellness, Bap*st Health South Florida;

Voluntary Assistant Professor of Medicine,

University of Miami Miller School of Medicine

Miami, FL

Alvin (Al) Powers, MD Joe C. Davis Chair in Biomedical Science;

Professor of Medicine, Molecular Physiology

and Biophysics; Director, Vanderbilt Diabetes

Center; Chief, Division of Diabetes, Endocrinolo-

gy, and Metabolism, Vanderbilt University

School of Medicine

Nashville, TN

Lital Reitblat, MD, MS Pediatric Endocrinologist

Broward Health

Fort Lauderdale, FL

Julie Rodman, OD, MS, FAAO Associate Professor of Optometry

Nova Southeastern University

Fort Lauderdale, FL

Marile Santamarina, MS, PharmD,

CPh, CDE, CPT Assistant Professor of Pharmacy Prac*ce,

Palm Beach Atlan*c University; Cleveland Clinic

West Palm Beach, FL

Teresa J. Sakraida, MS, MSED, PhD,

RN Associate Professor



Boca Raton, FL

Stanley Schwartz, MD Associate Professor, University of Pennsylvania;

Director of Diabetes Program, Philadelphia

Heart Ins*tute

Philadelphia, PA

David Sutherland, MD, PhD Emeritus Professor of Surgery

University of Minnesota

Minneapolis, MN

Stacy Winton, MS, RDN, LD/N Clinical Nutri*onist

Memorial Regional Hospital

Hollywood, FL

S p e a ke r s a n d P r e s e n t e r s

Monique Biddle, RD, LD, CDE

Diabetes Nutrition Specialist

Memorial Regional Hospital

Diabetes Center

Hollywood, FL

Lois Exelbert, RN, CDE, MS, BC-ADM

Manager,

Baptist Hospital Diabetes Care Center

Miami, FL

Siobhan Gross, RN, BSN, CDE

Registered Nurse,

Certified Diabetes Educator

Jupiter Medical Center

Jupiter, FL

Alan Jacobson, BS, RPh, DPM

Retired

Andrea Jacobson, RN, BSN, CDE

RN Pediatric Endocrinology

Joe DiMaggio Children’s Hospital

Hollywood, FL

Mudit Jain, MD, FACE, ECNU, CDE

Director

Diabetes & Thyroid Care Center of

Excellence

Plantation, FL

Jeanna Rhoulhac, RDN, CDE, CDTC,

LD/N

Broward Health,

Community Health Services

Clinical Nutri*onist

Specialty Care Center

Fort Lauderdale, FL

Teresa J. Sakraida, MS, MSED, PhD, RN

Associate Professor



Boca Raton, FL

Marile Santamarina, MS, PharmD, CPh,

CDE, CPT

Assistant Professor

Palm Beach Atlan*c University

Palm Beach, FL

Thelma Williams, RN, MSN-ED, BSN, NCC,

CNS, DNS

Program Manager

Florida Medical Center

Lauderdale Lakes, FL


P l a n n i n g C o m m i t t e e

Paul Aoun, DO, PhD

Disclosed no conflict of interest.

Pamela C. Arnold, MSN, APRN, BC-ADM,

CDE


Katherine Chadwell, DNP, MBMSc, ARNP,

GNP-BC, CPHQ


James R. Gavin III, MD, PhD

Board Member/Advisory Panel: Abbo1

Diabetes Care; Intarcia Pharmaceu*cals;

Janssen Pharmaceu*cals

Consultant: Intarcia Pharmaceu*cals; Novo

Nordisk

Speaker’s Bureau: AstraZeneca; Boehringer

Ingelheim; Janssen Pharmaceu*cals

Harvi Lipshultz, PharmD



Speaker’s Bureau: AstraZeneca; Boehringer

-Ingelheim; Lilly

Michael Ozner, MD, FACC, FAHA

Scien*fic Advisory Board: Life Extension;

Nordic Naturals

Alvin (Al) Powers, MD


Lital Reitblat, MD


Julie Rodman, OD, MS, FAAO

Consultant: Optorue


CDE, CPT


Teresa J. Sakraida, MS, MSED, PhD, RN


Stanley Schwartz, MD

BoardMember/Advisory Panel: Janssen;

Merck; AstraZeneca; Boehringer-

Ingelheim; Lilly; Salix, Novo Nordisk, Gene-

sis Biotech

Consultant: NIH ROIDK085212

Speaker’s Bureau: Janssen; Merck; Astra-

Zeneca; Boehringer-Ingelheim; Lilly; Salix,

Novo Nordisk, Eisai, Inc.; Amgen

Stock Holder: Saturn

David Sutherland, MD, PhD


Stacy Winton, MS, RDN, LD/N


S p e a ke r s a n d P r e s e n t e r s

Monique Biddle, RD, LD, CDE Disclosed no conflict of interest.

Lois Exelbert, RN, MS, CDE, BC-ADM,

LCCE


Siobhan Gross, RN, BSN, CDE Disclosed no conflict of interest.

Alan Jacobson, BS, RPh, DPM Disclosed no conflict of interest.

Andrea Jacobson, RN, BSN, CDE Disclosed no conflict of interest.


Speaker’s Bureau: AstraZeneca;

Boehringer-Ingelheim; Lilly

Jeanna Rhoulhac, RDN, CDE, CDTC,

LD/N Disclosed no conflict of interest.

Teresa J. Sakraida, MS, MSED, PhD,

RN Disclosed no conflict of interest.


CDE, CPT


Thelma Williams, RN, MSN-ED Disclosed no conflict of interest.


As an accredited provider of con*nuing educa*on, it is the Associa*on’s policy to ensure balance, inde-

pendence, objec*vity, and scien*fic rigor in all of its educa*onal ac*vi*es. All par*cipa*ng faculty and

planning commi1ee members are required to disclose to the program audience any financial rela*on-

ships related to the subject ma1er of this program. Disclosure informa*on is reviewed in advance in or-

der to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide

par*cipants with informa*on on which they can make their own judgments.

D i s c l o s u r e I n f o r m a t i o n


P R O G R A M S C H E D U L E

7:00 AM - 7:45 AM Registra*on

Con*nental Breakfast

Exhibits Open

7:45 AM - 8:00 AM Welcome - Mitchell Cypress, President of the Seminole Tribe of Florida

8:00 AM - 9:00 AM New Theories of Classifying Diabetes

Stanley Schwartz, MD

9:00 AM - 10:00 AM Cardiovascular Disease: Reflec:ng Back and Moving Forward

Michael Ozner, MD, FACC, FAHA

10:15 AM - 11: 15 AM History and Current Status of Pancreas Transplanta:on

David Sutherland, MD

11:15 AM- 12:15 PM Herbal Remedies for Adjunc:ve Treatment of Diabetes

Harvi Anne Lipshultz, PharmD

12:15 PM- 1:00 PM Expert Panel with Q & A

Stanley Schwartz, MD; Michael Ozner, MD, FACC, FAHA;

David Sutherland, MD; Harvi Anne Lipshultz, PharmD

1:00 PM—2:30 PM LUNCH BREAK

10:00 AM - 10:15 AM MID-MORNING BREAK & EXHIBITS

KEYNOTE SESSIONS

2:30 PM—4:30 PM AFTERNOON WORKSHOPS

GRAND BALLROOM C GRAND BALLROOM D MTG. ROOMS 1 & 2

2:30 pm - 3:30 pm

Pharmacy in Your Pantry

Stacy Winton, MS, RDN, LD/N

Diabe:c Re:nopathy

Eye Update

Julie Rodman, OD, FAAO

Diabetes and Personalized

Healthcare—Why Genes MaEer

Katherine Chadwell, DNP, MBMSc,

ARNP, GNP-BC, CPHQ

3:30 pm - 4:30 pm

SGLT-2 Inhibitors:

Review of Safety Issues


CDE, CPT

Health Behavior Change:

An Update on the State of the

Science and Future Think

Teresa Sakraida, MS, MSED, PhD, RN

Exercise Concerns

in Youth with Type 1

Lital Reitblat, MD

7:00 AM - 7:45 AM Registra*on

Con*nental Breakfast

Exhibits Open

7:45 AM - 8:00 AM Welcome

8:00 AM - 9:00 AM Diabetes Epidemiology: Guiding Clinical and Public Health Prac:ce

Jim Gavin, MD, PhD

9:00 AM—10:00 AM Diabetes Management in the Hospital SeFng

Pamela C. Arnold, RN, MSN, CDE, APRN

10:15 AM - 11:15 AM Effec:ve Solu:ons to Common Diabetes Care Challenges

Paul Aoun, DO, PhD

11:15 AM - 12:15 PM Recent Advances in Pharmacotherapy for Type 2 Diabetes


12:15 PM - 1:15 PM Changes in the Understanding of Pathogenesis of Type 1 Diabetes: Implica:ons for

Preven:on and Treatment

Al Powers, MD

10:00 AM - 10:15 AM MID-MORNING BREAK & EXHIBITS


P R O G R A M S C H E D U L E

KEYNOTE SESSIONS

Presentation Handouts

Just as a reminder, in an effort to go green, select presenta*on handouts are located on our website and

available for download: professional.diabetes.org/sfl

Successful Completion Statement

Cer*ficates of Comple*on/A1endance are provided to registered a1endees based upon comple*on of the

online evalua*on that will be available at h1p://professional.diabetes.org/sfl through September 30 2016.

For ques*ons regarding con*nuing educa*on, please contact professionaleduca*[email protected]

PERSONAL SESSION TRACKING WORKSHEET FOR PHARMACIST

**Double Credit will not be awarded for sessions occurring at the same time.

Time Sessions Number of

credits/hours

Friday, September 9, 2016

8:00 am - 9:00 am New Theories of Classifying Diabetes

UAN: 0239-0000-16-302-L01-P

At the end of this presenta:on, the par:cipant should be able to:

• Discuss the benefits and challenges with exis*ng classifica*on of diabetes

mellitus

1.0

9:00 am—10:00 am Cardiovascular Disease: Reflec:ng Back and Moving Forward

UAN: 0239-0000-16-303-L01-P


• Iden*fy the root cause of atherosclerosis

• Explore the cri*cal role of therapeu*c lifestyle interven*on for

cardiometabolic health

• Indicate key cardiac risk factors and learn how to reverse them

1.0

10:15 am—11:15 am History and Current Status of Pancreas Transplanta:on

UAN: 0239-0000-16-304-L01-P


• Describe the history of pancreas transplanta*on

• Outline guidelines for pa*ent elec*on for pancreas transplanta*on

• Describe current pancreas transplanta*on outcomes for pa*ents

1.0

11:15 am - 12:15 pm Herbal Remedies for the Adjunc:ve Treatment of Diabetes

UAN: 0239-0000-16-305-L01-P


• Outline unbiased, historically and clinically significant data on the

adjunc*ve use of herbal remedies in diabe*c pa*ents.

1.0

12:15pm—1:00 PM Expert Panel with Q&A

UAN: 0239-0000-16-306-L01-P


• Discuss the ADA/AACE glycemic targets in the hospital.

• Discuss the benefits and challenges with exis*ng classifica*on of diabetes

mellitus

0.75


Time Concurrent Sessions Number of

credits/hours

Friday, September 9, 2016

2:30 pm - 3:30 pm Pharmacy in Your Pantry

UAN: 0239-0000-16-307-L01-P


• Describe the impact of diabetes on the eye including classifica*on and

treatment.

1.0

Diabe:c Re:nopathy Eye Update

UAN: 0239-0000-16-308-L01-P


• Describe the impact of diabetes on the eye including classifica*on and

treatment.

1.0

Diabetes and Personalized Healthcare—Why Genes MaEer

UAN: 0239-0000-16-309-L01-P


• Summarize the personalized healthcare ini*a*ve

• Define the basic concepts of gene*cs, genomics, and epigene*c

• Iden*fy the role of the healthcare provider in the treatment and

development of diabetes from a personalized approach to diabetes

1.0

3:30 pm - 4:30 pm SGLT-2 Inhibitors: Review of Safety Issues

UAN: 0239-0000-16-310-L01-P


• Describe the mechanism of ac*on of SGLT2 inhibitors.

• List the 3 most common side effects of SGLT2 inhibitors.

• State 3 monitoring parameters that individuals using an SGLT2 inhibitor

should performed to prevent or early detect DKA, a rare side effects of

SGLT2 inhibitors.

1.0

Health Behavior Changes: An Update on the State of the Science and Future

Think

UAN: 0239-0000-16-311-L01-P


• List barriers to diabetes self-management.

• Outline the state of the science literature about health behavior change.

1.0

Exercise Concerns in Youth with Type 1

UAN: 0239-0000-16-312-L01-P


• Iden*fy challenges for young people with Type 1 diabetes when trying to

exercise

• Explain the physiology of glucose u*liza*on during exercise in Type 1

diabetes.

• Iden*fy ways to promote euglycemia during and aGer exercise for your

people with Type 1 diabetes.

1.0

Total for

Friday 6.75







Time Sessions Number of

credits/hours

Saturday, September 10, 2016

8:00 am - 9:00 am Diabetes Epidemiology: Guiding Clinical and Public Health Prac:ce

UAN: 0239-0000-16-313-L01-P


• Describe the influence epidemiological findings have had on clinical

and public health approaches to trea*ng diabetes

1.0

9:00 am—10:00 am Diabetes Management in the Hospital SeFng

UAN: 0239-0000-16-314-L01-P


• Discuss the ADA/AACE glycemic targets in the hospital.

1.0

10:15 am - 11:15 am

Effec:ve Solu:ons to Common Diabetes Care Challenges

UAN: 0239-0000-16-315-L01-P


• Iden*fy the mechanism of ac*on, advantages and disadvantages of

available agents used in the treatment of type 2 diabetes.

1.0

11:15 am—12:15 pm

Recent Advances in Pharmacotherapy for Type 2 Diabetes

UAN: 0239-0000-16-316-L01-P


• List the drug classes for treatment of type 2 diabetes.

1.0

12:15 pm - 1:15 pm

Changes in the Understanding of Pathogenesis of Type 1 Diabetes:

Implica:ons for Preven:on and Treatment

UAN: 0239-0000-16-317-L01-P


• Describe the history of pancreas transplanta*on.

1.0

Total for

Saturday 5.0

TOTAL CREDIT HOURS AVAILABLE OVERALL

TOTAL: 11.75

TOTAL CREDIT HOURS EARNED


Exhibitors AstraZeneca

Bap*st Health South Florida

Janssen Pharmaceu*cal Inc.

Lilly, USA LLC

Merck

Novo Nordisk

PTS Diagnos*cs

P&G

Sanofi

TrialNet

Bap*st Health South Florida

Humana

MannKind Corp.

Memorial Healthcare System

P&G

Thank You To Our Generous

Sponsors and Supporters!

PRODUCT THEATER

Presented by MannKind Corp.

1:00 p.m. – 2:00 p.m. LUNCH PRODUCT THEATER ~ Grand Ballroom A & B

Update on Prandial Insulin for the Treatment of Type 1 Diabetes – Affinity 1 Study

Dr. Mudit Jane, Dr. Mudit Jane, Dr. Mudit Jane, Dr. Mudit Jane, MD, FACE, ECNU, CDE

MannKind Corpora*on is a biopharmaceu*cal company focused on the discovery, development and

commercializa*on of therapeu*c products for pa*ents.

AFREZZA® (pronounced uh-FREZZ-uh), approved in 2014 by the U.S. Food and Drug Administra*on is

a rapid-ac*ng inhaled insulin therapy indicated to improve glycemic control in adults with diabe-

tes. Taken at the start of a meal using a specially designed inhaler, Afrezza dissolves rapidly upon

inhala*on to the deep lung and delivers insulin quickly to the bloodstream. Peak insulin levels are

achieved within 12 to 15 minutes of use and help to control post-meal blood sugar spikes that affect

HbA1C levels.

AFREZZA u*lizes our proprietary Technosphere® formula*on technology , which is based on a class

of organic molecules that are designed to self-assemble into small par*cles onto which drug mole-

cules can be loaded. We believe Technosphere represents a versa*le drug delivery plaVorm that

may allow pulmonary administra*on of certain drugs that currently require administra*on by injec-

*on, such as GLP-1. Pulmonary administra*on provides convenience for the pa*ent and we believe

a major advantage of drugs inhaled as Technosphere formula*ons is that they have been shown to

be absorbed very rapidly into the arterial circula*on, essen*ally mimicking intra-arterial administra-

*on. MannKind is also developing other inhala*on technologies, including an innova*ve line of pa-

*ent-focused, breath-ac*vated, dry powder inhalers and inhala*on profiling to characterize pa*ent

inhala*on.

*This program is sponsored by and the speaker is presen�ng on behalf of MannKind Corp. It is being presented

consistent with FDA guidelines and is not approved for con�nuing educa�on credit.


Silver Anniversary ConferenceSilver Anniversary ConferenceSilver Anniversary ConferenceSilver Anniversary Conference on Diabetes Mellitus:


This ac:vity is supported, in part, by an educa:onal

grant from

Lilly, USA LLC

silver anniversary conference - american diabetes association · silver anniversary conference on...

Documents